Skip Ribbon Commands
Skip to main content
Sign In

Immunotherapy: Enabling Next-Generation Cancer Treatments

let's share perspective

Elutra®
Cell Separation System*
Overview How It Works Specifications Materials
Collaboration Collection Separation Expansion

Cell-based immunotherapy is currently at the forefront in the development of new treatments for serious diseases. For example, genetically modified autologous T-cells expressing chimeric antigen receptors (CAR) are generating sustained remissions for certain indications.1 Terumo BCT is proud to be a source of cell collection, expansion and separation technologies used in the production process for these potentially groundbreaking and lifesaving therapies.

CAR T-cell therapies are in clinical trials and have not yet received regulatory approval for the treatment of any disease or condition.


Does everyone have the same challenges that I have?
—Director of Cell Therapies

You see cellular immunotherapy from a unique perspective. We see it through the lens of 30 years of industry expertise in cell processing and apheresis collections. Imagine what we could do when we collaborate.


Making big leaps in medicine is not for the faint of heart. You are tasked with creating innovative therapies, commencing clinical trials and developing robust manufacturing processes. We believe that sharing insight can help all of us break through these challenges. Let’s start by sharing perspective.






How can we optimize apheresis collections?
—Apheresis Unit Director

Beginning with a quality starting product is the best way to impact the quality of a final product. We have highlighted some of the core challenges in achieving the best collection:


Variability

There are many ways to reduce variability and optimize quality collections, including:
  • Choosing a collection device
  • Selecting an appropriate protocol
  • Developing clear SOPs
  • Creating leukapheresis manuals

Communication

Are the key downstream players communicating well with their upstream counterparts? When a manufacturer provides feedback to the apheresis unit about the success level of its collections, only then can an optimized starting product be achieved.





Let's gain perspective

Discover the Spectra Optia® Apheresis System and how it delivers high target cell collection with low non-target cell contamination, driving consistency and reproducibility, all backed by Terumo BCT's more than 30 years of experience in apheresis collection technology.





Cost of goods is a huge problem for this industry.
—Manufacturing EVP, Biotechnology

Where's that sweet spot that delivers a quality product at a cost that can support your goals? Start by identifying where you can gain efficiencies in your process. One study of the Elutra system2 showed how clinical-scale, closed-system elutriation performed efficiently for the selective enrichment of lymphocytes for immunotherapy protocols. It showed an improvement in cost, yield and purity over methods that required the addition of monocyte-depleting beads.









Let's refine perspective

Discover the The Elutra® Cell Separation System provides a standardized and consistent method for separating cell populations, making it well suited for the enrichment of lymphocytes prior to isolation and expansion for T-cell therapies. The Elutra system offers greater than 65 percent recovery of both monocytes and lymphocytes, as well as greater than 75 percent purity.2

Customers are responsible for validating the use of the Elutra system to separate cells for their intended therapy.





As an academic researcher, what can give me an edge in manufacturing?
—Lab Director

Researchers—Plan now to scale later.

Even if your work is still in the early stages, you can look ahead to the challenges of clinical trials and commercialization. Early adoption of an automated cell culture platform may help reduce process complexity and give you increased confidence in your manufacturing process during scale-up or scale-out.

Commercial Manufacturers—Combine protocol flexibility and process automation.

See how cell culture processes can be optimized on an automated cell culture platform to match the needs of a particular cell type.






Let's grow perspective

The Quantum® Cell Expansion System provides a solution for expansion of cells used in adoptive transfer therapies, including promising work in the area of T-cell therapies.1 The Quantum system has also been used to produce viral vectors, including lentivirus, and to support other areas of cancer research, such as the expansion of stable tumor lines and ex vivo maturation of dendritic cells.3

Customers are responsible for validating the use of the Quantum system to expand cells for their intended therapy.





Customers are responsible for validating the use of the Quantum system to expand cells for their intended therapy.
Customers are responsible for validating the use of the Elutra system to separate cells for their intended therapy.
1Maude S, et al., "Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia." New England Journal of Medicine 2014; 371: 1507–1517.
2Powell DJ, Brennan AL, Zheng Z, et al., "Efficient Clinical-Scale Enrichment of Lymphocytes for Use in Adoptive Immunotherapy Using a Modified Counterflow Centrifugal Elutriation Program." Cytotherapy 2009; 11 (7): 923–935.
3Startz T, Nguyen K, Peters R, et al. Maturation of dendritic cells from CD14+ monocytes in an automated functionally closed hollow fiber bioreactor system. Cytotherapy. 2014;16(4):S29.

CAR-T Cell Therapies From the Transfusion Medicine Perspective



Click the link below to view the "CAR-T Cell Therapies From the Transfusion Medicine Perspective" Article.

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells



Click the link below to view the "Elutriated lymphocytes for manufacturing chimeric antigen receptor T-cells" Article.

Expansion of T-Cells in an Automated, Functionally Closed Hollow-Fiber Bioreactor System



This white paper demonstrates the expansion of T-cells in the Quantum® Cell Expansion System.

Results from a single stimulation event showed that the Quantum system produced 90- to 500-fold expansion of T-cells starting from an apheresis blood collection in as little as 13 days.

The enhanced manufacturing process control of an automated and functionally closed system can help reduce the labor and the number of open events involved in T-cell expansion, which may result in more efficient production and scale-out of cellular production.

Click the link below to signup and view this read.

Get access

​​​​​​​​​​​​​​​​​​​​​